× ×ª×× × ×ª×¨×פ×
××רש×
| ××× ×× ×× × ×ספ××
|
|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
L01EX
Other protein kinase inhibitors
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
פ××× - PER OS
|
| צ×רת ××× ××
|
×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Renal cell carcinoma (RCC)Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 23/01/2011
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×§× ××פ×× ×תק×× (×©× × ×××××) ×סרק××× ×תק××ת ×©× ×רק××ת ×ר××ת ×ס×× ×¡×¨×§××× ×¤××ר×××ס××ת, סרק××× ×¤××ר×××ס×××צ×××ת, ××××××סרק×××, סרק××× ×¡×× ××××××ת, MPNST, NOS, סרק××× ×סק×××ר×ת, malignant glomus tumors |
09/01/2013 |
××× ×§×××××× |
|
Soft tissue sarcoma |
|
| ×××פ×× ×סר×× ×××× ×תק×× ×× ×ר××¨×ª× (×× ××§× ××פ×× ×¨×ש××). ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ××©×ª× ×ª×¨×פ×ת ×××× ××תר×פ×ת ××פ×ר××ת ×××× - Sunitinib, Sorafenib, Everolimus, Temsirolimus, Pazopanib |
23/01/2011 |
××× ×§×××××× |
|
Renal cell carcinoma |
|
| סר×× ×××× ×תק×× ×× ×ר××¨×ª× (×× ××§× ××פ×× ×¨×ש××). |
30/01/2020 |
××× ×§×××××× |
|
Renal cell carcinoma |
|
| סר×× ×××× ×תק×× ×× ×ר××¨×ª× (×× ××§× ××פ×× ×¨×ש××). ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×ש××ש תר×פ×ת ×××× ××תר×פ×ת ××פ×ר××ת ×××× - Sunitinib, Sorafenib, Everolimus, Temsirolimus, Pazopanib, Axitinib, Nivolumab. ×××פ×× ×ת×ש×ר ×× ××× ×ª× ×ש×××× ×¢× Nivolumab ×× ×¢× ×ª×¨××¤× ××שפ×ת ××¢××× mTOR. |
12/01/2017 |
××× ×§×××××× |
|
Renal cell carcinoma |
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×. ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- 1. סר×× ×××× ×תק×× ×× ×ר××¨×ª× (×× ××§× ××פ×× ×¨×ש××).
- 2. ×§× ××פ×× ×תק×× (×©× × ×××××) ×סרק××× ×תק××ת ×©× ×רק××ת ×ר××ת ×ס×× ×¡×¨×§××× ×¤××ר×××ס××ת, סרק××× ×¤××ר×××ס×××צ×××ת, ××××××סרק×××, סרק××× ×¡×× ××××××ת, MPNST, NOS, סרק××× ×סק×××ר×ת, malignant glomus tumors
- ×. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ××××× ×××ר×××××× ××××¤× ×××ר×××××× ××× ×§×××××ת.
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 15/05/19
GLAXO
×××ר××× × - Votrient
true
השינוי האחרון נעשה בֹ־21 ביולי 2025 ב־16:07
